VivoSeq
Other

Locally Advanced or Metastatic NSCLC

0

Pipeline Programs↗

22

Active Trials↗

16

Companies Involved↗

Locally Advanced or Metastatic NSCLC is an early-stage landscape with 0 programs across 16 companies. The most active players are Avistone Biotechnology Co., Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd., AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

70/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avistone Biotechnology Co., Ltd.

0 programs

PreclinicalJ

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalJiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

0 programs

PreclinicalD

Dizal Pharmaceuticals

0 programs

PreclinicalC

CSPC Megalith Biopharmaceutical Co.,Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

38

clinical trials

Recruiting12 · 32%
Completed7 · 18%
Active, not recruiting6 · 16%
Unknown status6 · 16%
Not yet recruiting4 · 11%
Terminated2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

38 trials

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Recruiting·AAvistone Biotechnology Co., Ltd.·Phase 2·NCT06574347·120 enrolled
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06929936·33 enrolled
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT06674343·144 enrolled
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Recruiting·KKiromic BioPharma Inc.·Phase 1·NCT06069570·48 enrolled
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Recruiting·TTeligene US·Phase 2·NCT06010329·66 enrolled
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Recruiting·DDizal Pharmaceuticals·Phase 2·NCT06276283·60 enrolled
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT05631249·40 enrolled
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Recruiting·BBlossomHill Therapeutics·Phase 1/2·NCT06706076·266 enrolled
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Recruiting·PPierre Fabre Medicament·Phase 1/2·NCT06567015·171 enrolled
H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
Recruiting·RRedCloud Bio·Phase 1/2·NCT05552781·76 enrolled
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Recruiting·DDizal Pharmaceuticals·Phase 1/2·NCT07070440·100 enrolled
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Recruiting·GGuangdong Association of Clinical Trials·N/A·NCT07696832·265 enrolled
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Active, not recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 3·NCT04143607·337 enrolled
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Active, not recruiting·RRemeGen Co., Ltd.·Phase 1·NCT06883630·121 enrolled
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Active, not recruiting·HHutchison Medipharma Limited·Phase 3·NCT05009836·320 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)